Abstract
Allergic diseases (ADs) are a major concern when it comes to public well‐being. Moringa oleifera Lam is a tropical plant that is used in traditional medicine due to the presence of isothiocyanate. The present study investigated the antiallergic properties of 4‐(α‐L‐rhamnopyranosyloxy)‐benzyl isothiocyanate or moringin isolated from Moringa oleifera seeds in the form of alpha‐cyclodextrin‐moringin (α‐CD/MG) complex on rat basophilic leukaemia (RBL‐2H3) cell line at both the early and late stages of an allergic reaction. The α‐CD/MG complex was initially elucidated using nuclear magnetic resonance (NMR) followed by the 3‐(4,5‐dimethylthiazol‐2‐yl)‐5‐(3‐carboxymethoxyphenyl)‐2‐(4‐sulfophenyl)‐2H‐tetrazolium inner salt proliferation assay to evaluate the cytotoxicity and cell viability with respect to ketotifen fumarate (KF) and α‐CD/MG. The release of beta‐hexosaminidase (β‐hexosaminidase) and histamine was used to determine the level of inhibition in the early stage while the suppression of the release of prostaglandin (PGD2), tumour necrosis factor‐alpha (TNF‐α), and interleukin (IL‐4) was considered in the late stage. Higher concentrations of α‐CD/MG (5 μM, p < 0.001) in mast cell degranulation significantly inhibited the expression of β‐hexosaminidase, histamine, TNF‐α, PGD2, and IL‐4 in both the early and late stages. Thus, α‐CD/MG can potentially be developed as an antiallergic drug as it has the ability to inhibit allergic responses in the late and early stages.